ColesAJWingMSmithS, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet1999; 354: 1691–1695.
2.
ColesAJCoxALe PageE, et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol2006; 253(1): 98–108.
3.
ColesAJTwymanCLArnoldDL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380: 1829–1839.
4.
CohenJAColesAJArnoldDL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380: 1819–1828.
5.
CossburnMPaceAAJonesJ, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology2011; 77: 573–579.
